The purpose of this study is to assess the pharmacokinetics (PK), bioavailability, immunogenicity, safety, and tolerability of ABBV-8736 following subcutaneous (SC) administration relative to intravenous (IV) administration.

Inclusion Criteria:

• Body mass index (BMI) is >= 18.0 to <= 32.0 kg/m2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
• Body weight >= 35 kg.
• A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead electrocardiogram (ECG).

Exclusion Criteria:

• Participant requires any over-the-counter and/or prescription medication, vitamins, and/or herbal supplements, on a regular basis.
• Participant uses any medications, vitamins and/or herbal supplements within the 14-day period prior to study treatment administration.
• Participant has received any treatment by injection within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study treatment administration.
• Participant has prior exposure to a Triggering Receptor Expressed on Myeloid Cells 1 (TREM1) agent.